Approved HIV Drugs
Approved HIV Drugs
HIV Drug Therapy: Once-daily Dolutegravir Superior to Darunavir at 96 Weeks
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 13 November 2014 00:00
- Written by Alain Volny-Anne
Treatment with a triple antiretroviral combination containing the once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported this month at the HIV Drug Therapy Glasgow conference.
HIV Drug Therapy: Darunavir/Ritonavir Protease Inhibitor Monotherapy Less Effective than 3-Drug ART
- Details
- Category: Approved HIV Drugs
- Published on Monday, 10 November 2014 00:00
- Written by Keith Alcorn
Monotherapy with ritonavir-boosted darunavir (Prezista) results in a lower rate of viral suppression after 48 weeks when compared to darunavir/ritonavir plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), but may be just as effective as 3-drug therapy in people with nadir (lowest-ever) CD4 cell counts above 200 cells/mm3, according to a 48-week analysis of the PROTEA study presented last week at the HIV Drug Therapy Glasgow conference.
HIV Drug Therapy: Efavirenz Compromises Hormonal Contraceptive Implant
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 04 November 2014 00:00
- Written by Keith Alcorn
The widely prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz substantially reduces levels of the hormonal contraceptive levonorgestrel, a component of a progesterone contraceptive implant widely used in developing countries, according to findings from a study conducted in Uganda presented this week at the HIV Drug Therapy Glasgow conference.
HIV Drug Therapy: Do Emtricitabine and Lamivudine Have Similar Efficacy for First-line ART?
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 04 November 2014 00:00
- Written by Michael Carter
First-line antiretroviral regimens containing emtricitabine have superior virological efficacy to combinations containing lamivudine when combined with tenofovir and either nevirapine or efavirenz, Dutch investigators report in the October 1 online edition of Clinical Infectious Diseases and at the HIV Drug Therapy Glasgow conference taking place this week. Lamivudine was associated a significantly increased risk of virological failure when used in these regimens.
IDWeek 2014: Earlier Treatment, NNRTI Use Predict Slower HIV Rebound After Stopping ART
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 22 October 2014 00:00
- Written by Liz Highleyman
HIV viral load usually begins to rise again within 4 to 8 weeks after stopping antiretroviral therapy (ART), though starting treatment earlier in the course of infection and using a non-nucleoside reverse transcriptase inhibitor (NNRTI) may delay viral rebound, according to study findings presented at IDWeek 2014 last week in Philadelphia.
More Articles...
- IDWeek 2014: NNRTIs and Protease Inhibitors Both Good for First ART, Channeling Affects Choices
- IDWeek 2014: Longer Use, Age, Low Body Weight Raise Risk of Tenofovir Kidney Problems
- HIV Positive Stimulant Users Benefit from Antiretroviral Therapy
- IDWeek 2014: Efavirenz Not Linked to Suicide in Analysis of Insurance Records
Web Design and Development by